Figure 4

3AC treatment inhibits MM cell growth in vivo. NOD/SCID/γcIL2R (NSG) mutant mice were challenged with 1 × 107 MM cells (OPM2) by intraperitoneal injection. Six h later, the mice received their first injection of 3AC, followed by a daily dose for the next 7 d and then a biweekly dose for the ensuing 15 wks. (A) Enzyme-linked immunosorbent assay quantitation of human (Hu) λ light chain present in the serum of OPM2 challenged mice (3AC- or vehicle-treated) and unchallenged mice as indicated. (B) Representative FACS detection and quantitation of human MM cells in the circulation of NSG mice is indicated. (C) Box and whisker plots showing the mean, range and standard deviation for MM detected by flow cytometry in the indicated electronic gate in (B). (D) Survival of 3AC and vehicle treatment (Veh) groups that were challenged with MM cells (n = 11/group). (E) Western blot analysis of SHIP2 expression in MM tumors recovered from vehicle-treated (Veh) or 3AC-treated mice. PBMC, peripheral blood mononuclear cells.